Elucidating the role of trained immunity in kidney transplant patients

阐明训练有素的免疫力在肾移植患者中的作用

基本信息

  • 批准号:
    10642596
  • 负责人:
  • 金额:
    $ 31.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2028-03-31
  • 项目状态:
    未结题

项目摘要

SUMMARY – PROJECT 1 Historically, organ transplant immunologists have focused on the adaptive immune system, as organ rejection is mediated primarily by T cells. However, accumulating evidence indicates a distinct role for innate immune cells in the complex graft-reactive immune response. This P01’s investigators propose to modulate innate immune responses by targeting trained immunity, a long-term increase in the functional responsiveness of innate immune cells, which is maintained by epigenetic modifications and can be considered de facto innate immune memory. The members of Project 1 recently demonstrated in a mouse model of heart allograft transplantation that graft rejection can be prevented by therapeutically regulating trained immunity. Suppressing trained immunity yielded a tolerogenic milieu characterized by an accumulation of regulatory macrophages and regulatory T cells in the allograft. This change in the allograft microenvironment resulted in long-term graft survival without requiring immunosuppressive therapy. These results are corroborated by preliminary data in kidney transplant patients, showing that trained immunity is associated with 10-year graft survival. Based on these preclinical and clinical preliminary data, Project 1’s overall hypothesis is that trained immunity promotes graft rejection in kidney transplant patients. In Aim 1, we will study which circulating factors (e.g., danger-associated molecular patterns and proinflammatory cytokines) are produced as a result of ischemia-reperfusion injury during transplantation and how these impact graft survival by inducing trained immunity. Durable trained immunity requires epigenetic changes in bone marrow myeloid progenitors. In Aim 2, we will investigate how changes in the bone marrow influence the production and behavior of circulating monocytes and relate this to clinical outcomes, including graft survival. To accomplish these Aims, we have assembled a multidisciplinary team of investigators led by Project Lead Dr. Mulder, who will coordinate Project 1 and supervise a team of experienced co-Is: Dr. Duivenvoorden is a transplant nephrologist and will be responsible for the studies on kidney transplant patients, Drs. Mhlanga and Netea will be responsible for all RNA- and ATAC-sequencing in close collaboration with Core C. Project 1 will yield critical insights into the relation between trained immunity and graft survival in kidney transplant patients. These insights will open new diagnostic and therapeutic avenues for advancing patient care.
摘要-项目1 从历史上看,器官移植免疫学家一直专注于适应性免疫系统,因为器官排斥反应是一种免疫系统。 主要由T细胞介导。然而,越来越多的证据表明,先天免疫细胞的独特作用 在复杂的移植物反应性免疫反应中。P01的研究人员提出调节先天免疫 通过针对训练的免疫反应,先天免疫系统功能反应的长期增加, 细胞,这是维持表观遗传修饰,可以被认为是事实上的先天免疫记忆。 项目1的成员最近在小鼠心脏同种异体移植模型中证明, 排斥反应可以通过治疗性调节训练的免疫来预防。抑制训练免疫产生了 致耐受性环境,其特征在于调节性巨噬细胞和调节性T细胞在细胞中的积累。 同种异体移植同种异体移植物微环境的这种变化导致了移植物的长期存活,而不需要 免疫抑制治疗这些结果得到了肾移植患者的初步数据的证实, 表明训练过的免疫力与10年移植存活率有关。基于这些临床前和临床 根据初步数据,项目1的总体假设是,训练的免疫促进肾脏移植物排斥反应。 移植患者 在目标1中,我们将研究哪些循环因素(例如,炎症相关分子模式和促炎性 细胞因子)作为移植期间缺血-再灌注损伤的结果而产生,以及这些细胞因子如何影响 通过诱导训练的免疫来维持移植物存活。持久训练的免疫力需要骨骼的表观遗传变化 骨髓髓系祖细胞。在目标2中,我们将研究骨髓中的变化如何影响 循环单核细胞的产生和行为,并将其与包括移植物存活在内的临床结果相关联。 为了实现这些目标,我们组建了一个由项目负责人Dr. 穆德,谁将协调项目1和监督一个团队的经验丰富的合作是:博士。 移植肾病学家,并将负责对肾移植患者的研究,Mhlanga博士和 Netea将与Core C密切合作,负责所有RNA和ATAC测序。 项目1将产生关键的见解训练免疫和移植肾存活之间的关系, 移植患者这些见解将为推进患者护理开辟新的诊断和治疗途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Willem Mulder其他文献

Willem Mulder的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Willem Mulder', 18)}}的其他基金

Stress-induced trained immunity in cardiovascular disease
心血管疾病中压力诱导的免疫力训练
  • 批准号:
    10635427
  • 财政年份:
    2017
  • 资助金额:
    $ 31.04万
  • 项目类别:
Translational imaging and nanomedicine in inflammatory atherosclerosis
炎症性动脉粥样硬化的转化成像和纳米医学
  • 批准号:
    10116448
  • 财政年份:
    2017
  • 资助金额:
    $ 31.04万
  • 项目类别:
Anti-inflammatory nanoparticle formulations to treat atherosclerosis
治疗动脉粥样硬化的抗炎纳米颗粒制剂
  • 批准号:
    8696070
  • 财政年份:
    2014
  • 资助金额:
    $ 31.04万
  • 项目类别:
Anti-inflammatory nanoparticle formulations to treat atherosclerosis
治疗动脉粥样硬化的抗炎纳米颗粒制剂
  • 批准号:
    9279233
  • 财政年份:
    2014
  • 资助金额:
    $ 31.04万
  • 项目类别:
PET/MRI to study nanotherapy in atherosclerosis
PET/MRI 研究动脉粥样硬化的纳米疗法
  • 批准号:
    8962168
  • 财政年份:
    2014
  • 资助金额:
    $ 31.04万
  • 项目类别:
PET/MRI to study nanotherapy in atherosclerosis
PET/MRI 研究动脉粥样硬化的纳米疗法
  • 批准号:
    8801993
  • 财政年份:
    2014
  • 资助金额:
    $ 31.04万
  • 项目类别:
A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and Therapy
用于乳腺癌诊断和治疗的表面活性纳米乳平台
  • 批准号:
    8699161
  • 财政年份:
    2011
  • 资助金额:
    $ 31.04万
  • 项目类别:
A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and Therapy
用于乳腺癌诊断和治疗的表面活性纳米乳平台
  • 批准号:
    8917868
  • 财政年份:
    2011
  • 资助金额:
    $ 31.04万
  • 项目类别:
A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and Therapy
用于乳腺癌诊断和治疗的表面活性纳米乳平台
  • 批准号:
    8507620
  • 财政年份:
    2011
  • 资助金额:
    $ 31.04万
  • 项目类别:
A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and Therapy
用于乳腺癌诊断和治疗的表面活性纳米乳平台
  • 批准号:
    8327177
  • 财政年份:
    2011
  • 资助金额:
    $ 31.04万
  • 项目类别:

相似海外基金

Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9212055
  • 财政年份:
    2016
  • 资助金额:
    $ 31.04万
  • 项目类别:
Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9348616
  • 财政年份:
    2016
  • 资助金额:
    $ 31.04万
  • 项目类别:
A CONFERENCE ON THE 'CRISIS' OF ACADEMIC MEDICAL CENTERS
关于学术医疗中心“危机”的会议
  • 批准号:
    6335654
  • 财政年份:
    2000
  • 资助金额:
    $ 31.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了